TIROFIBAN HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Medicure	AGGRASTAT	tirofiban hydrochloride	INJECTABLE;INJECTION	020912	NDA	Medicure International Inc	25208-001-04	1 VIAL, GLASS in 1 CARTON (25208-001-04) / 15 mL in 1 VIAL, GLASS	2016-10-15
Medicure	AGGRASTAT	tirofiban hydrochloride	INJECTABLE;INJECTION	020912	NDA	Medicure International Inc	25208-901-04	1 VIAL, GLASS in 1 CARTON (25208-901-04) / 15 mL in 1 VIAL, GLASS	2016-10-15
Medicure	AGGRASTAT	tirofiban hydrochloride	SOLUTION;INJECTION	020912	NDA	Medicure International Inc	25208-001-04	1 VIAL, GLASS in 1 CARTON (25208-001-04) / 15 mL in 1 VIAL, GLASS	2016-10-15
Medicure	AGGRASTAT	tirofiban hydrochloride	SOLUTION;INJECTION	020912	NDA	Medicure International Inc	25208-901-04	1 VIAL, GLASS in 1 CARTON (25208-901-04) / 15 mL in 1 VIAL, GLASS	2016-10-15
Medicure	AGGRASTAT	tirofiban hydrochloride	SOLUTION;INTRAVENOUS	020913	NDA	Medicure International Inc	25208-002-01	1 BAG in 1 CARTON (25208-002-01) / 100 mL in 1 BAG	1998-05-14
Medicure	AGGRASTAT	tirofiban hydrochloride	SOLUTION;INTRAVENOUS	020913	NDA	Medicure International Inc	25208-002-02	1 CONTAINER in 1 CARTON (25208-002-02) / 250 mL in 1 CONTAINER	1998-05-14
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the current manufacturing landscape for Tirofiban Hydrochloride Active Pharmaceutical Ingredient (API), identifying key suppliers, their capabilities, and relevant patent information. Understanding these factors is critical for pharmaceutical companies managing supply chain risks and R&D strategies for antiplatelet therapies.

Who are the Key Manufacturers of Tirofiban Hydrochloride API?

The production of Tirofiban Hydrochloride API is concentrated among a limited number of specialized manufacturers globally. These companies possess the technical expertise and regulatory compliance necessary for pharmaceutical-grade API synthesis.

Primary API Manufacturers:

Merck & Co., Inc.: While Merck & Co., Inc. (MSD outside the U.S. and Canada) is the originator of tirofiban and markets the branded product Aggrastat®, its internal API manufacturing capacity and external supplier relationships are proprietary. However, as the patent holder and primary marketer, it remains a central entity in the supply chain, either through direct production or contracted manufacturing.
Hospira, Inc. (now a subsidiary of Pfizer Inc.): Hospira has historically been a significant player in the generic API and finished dosage form markets for critical care drugs. Following its acquisition by Pfizer, it continues to operate, and its manufacturing capabilities likely include tirofiban hydrochloride API.
Other Contract Manufacturing Organizations (CMOs) and API Specialists: Several CMOs globally are equipped to produce complex APIs like tirofiban hydrochloride. These may include companies based in India and China, which are prominent in global API manufacturing due to cost efficiencies and established chemical synthesis infrastructure. Specific company names are often not publicly disclosed for proprietary reasons related to client confidentiality and supply agreements. However, typical CMOs with expertise in chiral synthesis and sterile API production are the likely candidates.

Factors Influencing Supplier Choice:

Regulatory Compliance: Manufacturers must adhere to Good Manufacturing Practices (GMP) standards set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.
Technical Expertise: Tirofiban hydrochloride is a complex non-peptide inhibitor of the platelet glycoprotein IIb/IIIa receptor. Its synthesis requires specialized chemical processes and stringent quality control.
Capacity and Scalability: Suppliers must demonstrate the ability to produce API in quantities required for commercial drug production and to scale up manufacturing if demand increases.
Supply Chain Security and Redundancy: Companies often seek multiple qualified suppliers to mitigate risks associated with geopolitical instability, natural disasters, or production disruptions.

What are the Key Patents and Intellectual Property Considerations?

The intellectual property surrounding tirofiban hydrochloride is primarily focused on its composition of matter, methods of synthesis, and pharmaceutical formulations. Understanding these patents is crucial for generic drug development and potential lifecycle management strategies.

Core Composition of Matter Patent:

The original patent protecting tirofiban hydrochloride as a novel chemical entity would have expired. However, the exact expiration dates vary by country and can be extended through mechanisms like patent term extensions in some jurisdictions.
U.S. Patent No. 5,281,571: This is a foundational patent related to tyrosyl derivatives, which includes tirofiban. While its primary term has long since expired, related patents and patent families often cover specific aspects of the compound or its manufacturing.

Manufacturing Process Patents:

Patents may exist for novel or improved synthetic routes that offer advantages in terms of yield, purity, cost-effectiveness, or environmental impact. These can extend market exclusivity even after the primary composition of matter patent expires.
Analysis of patent databases (e.g., USPTO, EPO, WIPO) reveals numerous patents and patent applications filed by Merck & Co. and others relating to tirofiban, its derivatives, and methods of preparation. For instance, patents might cover specific crystalline forms, polymorphic variations, or purification techniques that could be considered inventive.

Formulation and Medical Use Patents:

Patents related to specific pharmaceutical formulations (e.g., sterile solutions for intravenous administration) or novel medical uses of tirofiban may also be relevant. These can influence the market exclusivity of branded products and the timing of generic entry.

Generic Drug Development and Patent Litigation:

Generic manufacturers must navigate the patent landscape carefully. They typically aim to develop manufacturing processes that do not infringe on existing, unexpired process patents.
Patent litigation is common in the pharmaceutical industry, with originator companies seeking to enforce their patents and generic companies challenging their validity or seeking non-infringement declarations.
ANDA Filings and Paragraph IV Certifications: In the U.S., generic drug applicants file Abbreviated New Drug Applications (ANDAs). A Paragraph IV certification indicates that the applicant believes the patent(s) listed in the Orange Book for the reference listed drug are invalid, unenforceable, or will not be infringed by the proposed generic product. This often triggers patent litigation.

Example of Patent Activity:

While specific active patents can change and are subject to renewal, a broad search would reveal patent families covering aspects such as:

Synthesis of Tirofiban and its Intermediates: Patents detailing specific chemical steps, reagents, and conditions for producing tirofiban.
Purification Methods: Techniques to achieve the high purity required for pharmaceutical APIs.
Polymorphs and Solid Forms: Different crystalline structures of tirofiban hydrochloride, which can impact stability, bioavailability, and manufacturing properties.

What are the Regulatory Requirements for Tirofiban Hydrochloride API?

The manufacturing and supply of tirofiban hydrochloride API are subject to stringent regulatory oversight to ensure patient safety and drug efficacy.

Good Manufacturing Practices (GMP):

All API manufacturers must comply with current Good Manufacturing Practices (cGMP) as defined by major regulatory agencies. This includes regulations from the FDA (21 CFR Parts 210 and 211), EMA (EudraLex Volume 4), and other national health authorities.
Key GMP Aspects:
- Quality Management System: Robust systems for process control, change management, deviation handling, and corrective and preventive actions (CAPA).
- Facility and Equipment: Appropriate design, maintenance, and cleaning of manufacturing facilities and equipment to prevent contamination and ensure product quality.
- Personnel: Qualified and trained personnel involved in manufacturing, quality control, and quality assurance.
- Materials Control: Strict control over raw materials, intermediates, and finished APIs, including supplier qualification.
- Process Validation: Documented evidence that the manufacturing process consistently produces API meeting predefined specifications.
- Analytical Testing: Comprehensive testing of raw materials, in-process samples, and the final API to confirm identity, purity, strength, and quality.
- Stability Testing: Programs to assess the shelf-life and storage conditions of the API.

Drug Master Files (DMFs):

API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF contains confidential, detailed information about the manufacturing process, facilities, and controls for an API.
Types of DMFs:
- U.S. DMF: Submitted to the FDA.
- ASMF (Active Substance Master File) / CEP (Certificate of Suitability to the Monographs of the European Pharmacopoeia): Used in Europe.
Pharmaceutical companies (applicants for drug product marketing authorization) reference these DMFs in their applications (e.g., NDAs, ANDAs, MAAs). The regulatory agency reviews the DMF in conjunction with the drug product application.

Pharmacopoeial Standards:

Tirofiban hydrochloride must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define critical quality attributes, including:
- Assay: The acceptable range for the concentration of tirofiban hydrochloride.
- Impurities: Limits for specific known impurities and total impurities.
- Residual Solvents: Limits for solvents used in the manufacturing process.
- Water Content: Acceptable moisture levels.
- Chiral Purity: Given the chiral nature of tirofiban, stereoisomeric purity is critical.

Supply Chain Audits:

Companies that purchase tirofiban hydrochloride API for finished drug product manufacturing routinely conduct audits of their API suppliers to ensure ongoing compliance with GMP and quality agreements. These audits are a critical component of supplier qualification and ongoing supply chain management.

What are the Market Dynamics and Future Outlook for Tirofiban Hydrochloride API?

The market for tirofiban hydrochloride API is influenced by the demand for the finished drug product, the competitive landscape of branded versus generic products, and ongoing advancements in cardiovascular medicine.

Demand Drivers:

Acute Coronary Syndromes (ACS): Tirofiban hydrochloride is primarily used in patients with ACS, including unstable angina and non-ST-elevation myocardial infarction, often in conjunction with heparin and aspirin. Its use in percutaneous coronary intervention (PCI) procedures is also significant.
Aging Population: The global demographic shift towards an older population increases the incidence of cardiovascular diseases, driving demand for treatments like tirofiban.
Healthcare Access: Improved access to advanced cardiac care in emerging markets contributes to demand growth.

Competitive Landscape:

Branded Product: Merck & Co.'s Aggrastat® has been the reference product. Its market position is influenced by patent expiry and the introduction of generics.
Generic Competition: The availability of generic versions of tirofiban hydrochloride injections has increased significantly. This competition generally leads to lower prices for the finished drug product and, consequently, puts pressure on API pricing.
API Supplier Competition: The market for tirofiban hydrochloride API is competitive, with multiple qualified suppliers capable of meeting regulatory standards. Price, quality, reliability, and regulatory support are key differentiating factors for API manufacturers.

Future Outlook:

Sustained Demand: While newer antiplatelet agents (e.g., P2Y12 inhibitors) have emerged and may impact prescribing patterns in certain ACS scenarios, tirofiban hydrochloride remains a valuable therapeutic option, particularly in settings where cost-effectiveness and established efficacy are paramount.
Generic Market Dominance: The generic market for tirofiban hydrochloride is expected to continue to dominate, driven by cost pressures in healthcare systems.
API Sourcing Strategies: Pharmaceutical companies will continue to focus on securing reliable and cost-effective API sources. This may involve dual-sourcing strategies and closer collaboration with CMOs to ensure supply chain resilience.
Emerging Markets: Growth in the use of tirofiban hydrochloride in developing countries, where healthcare access is expanding, presents an opportunity for API manufacturers.

Key Market Considerations:

Pricing Pressure: Intense competition in the finished drug product market translates to significant pricing pressure on API manufacturers.
Quality and Regulatory Assurance: Despite price pressures, maintaining the highest standards of quality and regulatory compliance remains non-negotiable.
Innovation in Manufacturing: While the molecule is established, ongoing efforts by API manufacturers may focus on optimizing synthetic routes for improved efficiency, sustainability, and reduced impurity profiles.

Key Takeaways

The manufacturing of Tirofiban Hydrochloride API involves a specialized group of global suppliers with expertise in complex chemical synthesis and adherence to strict regulatory standards. Merck & Co. is the originator, but the API supply chain involves other CMOs and specialists, particularly in Asia, that cater to the generic market. Intellectual property, primarily related to manufacturing processes and formulations, plays a critical role in market dynamics. Compliance with cGMP, pharmacopoeial standards, and submission of DMFs are essential for market entry and sustained supply. The market for tirofiban hydrochloride API is characterized by sustained demand driven by cardiovascular disease prevalence, strong generic competition, and an ongoing focus on quality, reliability, and cost-effectiveness among API manufacturers.

Frequently Asked Questions

What are the primary therapeutic indications for tirofiban hydrochloride? Tirofiban hydrochloride is indicated for the treatment of patients with unstable angina or non-ST-elevation myocardial infarction, and it is also used in patients undergoing percutaneous coronary intervention (PCI).
Which regulatory agencies oversee the manufacturing of tirofiban hydrochloride API? Key regulatory agencies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national health authorities in other major markets. Manufacturers must comply with their respective Good Manufacturing Practices (GMP) guidelines.
How does patent expiry affect the tirofiban hydrochloride API market? The expiry of composition of matter patents for tirofiban hydrochloride has allowed for generic competition, leading to increased API supply from various manufacturers and downward pressure on API prices. However, process patents and formulation patents can still provide market protection.
What are the main quality control parameters for tirofiban hydrochloride API? Critical quality control parameters include assay, impurity profiles (related substances and stereoisomers), residual solvents, water content, and sterility for injectable grade API. Adherence to pharmacopoeial monographs (e.g., USP, Ph. Eur.) is mandatory.
What is a Drug Master File (DMF) and its role in tirofiban hydrochloride API supply? A Drug Master File (DMF) is a submission to a regulatory agency that contains confidential, detailed information about the manufacturing process, quality control, and facilities used for an API like tirofiban hydrochloride. Pharmaceutical companies reference these DMFs in their drug product applications, allowing regulators to assess the API quality without disclosing proprietary information to the drug product manufacturer.

Citations

[1] United States Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://patft.uspto.gov/

[2] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/

[3] World Intellectual Property Organization. (n.d.). Patentscope. Retrieved from https://patentscope.wipo.int/

[4] U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations Title 21. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm

[5] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Retrieved from https://ec.europa.eu/health/documents/eudralex

[6] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from https://www.uspnf.com/

[7] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from https://www.edqm.eu/

Suppliers and packagers for generic pharmaceutical drug: TIROFIBAN HYDROCHLORIDE